RadNet, Inc. Common Stock
RDNT
$77.28
+6.76%
RadNet, Inc. is a national provider of diagnostic imaging services, operating through two segments: Imaging Center and Digital Health. The Imaging Center segment offers a comprehensive range of imaging modalities including MRI, CT, PET, and mammography, while the Digital Health segment develops AI-driven clinical applications to enhance image interpretation and patient outcomes. As a market leader in the U.S. diagnostic imaging space, RadNet is distinct for its scale and its pioneering integration of AI into radiology workflows. The current investor narrative centers on the company's aggressive push into AI, highlighted by its $270 million acquisition of Gleamer, which positions RadNet as a leader in diagnostic automation. This strategic bet, combined with strong quarterly results, has fueled optimism about future growth and margin expansion, though the stock's recent volatility reflects ongoing debate about the execution and financial impact of these initiatives.…
RDNT
RadNet, Inc. Common Stock
$77.28
Related headlines
Investment Opinion: Should I buy RDNT Today?
Based on the data, RDNT is rated a Buy. The consensus recommendation is Strong Buy with an average target price of $89.75, implying a 29.7% upside from the current price of $69.22. The thesis is that RadNet's leadership in diagnostic imaging, combined with its strategic AI investments, will drive earnings growth and margin expansion, justifying the premium valuation.
Sign up to view all
RDNT 12-Month Price Forecast
The AI assessment is bullish with medium confidence. RadNet's strategic focus on AI, backed by the Gleamer acquisition, positions it for potential long-term growth, but the high valuation and execution risks warrant caution. The stock's strong revenue base and positive cash flow provide a foundation, while analyst sentiment is overwhelmingly positive. However, the high forward PE and thin margins mean that any misstep could lead to significant downside. I would upgrade the stance to high confidence if the company demonstrates tangible AI revenue contributions and margin expansion in the next two quarters, and downgrade to neutral if earnings miss or integration issues arise.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on RadNet, Inc. Common Stock's 12-month outlook, with a consensus price target around $89.75 and implied upside of +16.1% versus the current price.
Average Target
$89.75
0 analysts
Implied Upside
+16.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $100
Analyst target range
RadNet has coverage from 8 analysts, with a consensus recommendation of 'Strong Buy' (mean score of 1.25 on a 1-5 scale, where 1 is Strong Buy). The average target price is $89.75, implying a substantial upside of +29.7% from the current price of $69.22. The analyst sentiment is overwhelmingly bullish, with no Hold or Sell ratings, reflecting confidence in the company's AI strategy and growth prospects. The target price range spans from a low of $65.00 to a high of $100.00, indicating a wide spread of 54% between the low and high targets. This wide range suggests significant uncertainty about the pace of AI adoption and the financial impact of the Gleamer acquisition. The high target of $100 assumes successful integration and rapid revenue growth from AI products, while the low target of $65 implies potential execution risks or margin compression. The recent news of the Gleamer buyout and strong quarterly results likely drove the positive sentiment, but the wide target range highlights the speculative nature of the AI bet.
Bulls vs Bears: RDNT Investment Factors
RadNet presents a compelling growth story driven by its AI strategy and strong revenue base, but it carries significant execution and valuation risks. The bull case is supported by a unanimous Strong Buy rating, a 29.7% upside to the average target, and a low PEG ratio, while the bear case highlights the high forward PE, thin margins, and elevated debt. Currently, the bull side has stronger evidence given the analyst confidence and positive cash flow, but the key tension lies in whether the AI investments will translate into sustained earnings growth. If the Gleamer integration succeeds and margins expand, the stock could re-rate higher; if not, the high valuation could lead to a sharp correction.
Bullish
- Strong Buy consensus with 29.7% upside: All 8 analysts rate RDNT a Strong Buy (mean score 1.25), with an average target of $89.75 versus the current $69.22, implying a 29.7% upside. The low target of $65 is still near the current price, indicating limited downside risk from analyst estimates.
- AI acquisition positions for growth: The $270 million Gleamer acquisition positions RadNet as a leader in diagnostic automation, a strategic move that could drive future revenue growth and margin expansion. This aligns with the company's Digital Health segment focus on AI-driven clinical applications.
- Revenue growth robust at $3.05B: Estimated revenue for the current year is $3.05 billion, reflecting strong demand for diagnostic imaging services. This scale provides a solid base for leveraging AI investments and expanding market share.
- PEG ratio of 0.38 suggests undervaluation: With a PEG ratio of 0.38, the stock appears undervalued relative to its expected earnings growth. Analysts project EPS to turn positive to $1.22 next year, indicating a potential inflection point that the market may not fully price in.
Bearish
- High forward PE of 73.4x: The forward PE of 73.4x is elevated, reflecting high expectations for earnings recovery. If EPS growth falls short of the projected $1.22, the stock could face significant de-rating, as the current valuation leaves little room for error.
- Thin gross margin of 4.45%: Gross margin is only 4.45%, typical for imaging centers but vulnerable to reimbursement cuts and rising costs. Any margin compression could pressure profitability, especially as the company integrates Gleamer and invests in AI.
- Elevated debt-to-equity of 1.71: The debt-to-equity ratio of 1.71 indicates a leveraged balance sheet, which could strain cash flows if interest rates rise or earnings disappoint. This financial leverage amplifies downside risk in adverse scenarios.
- Stock below 52-week high by 19.4%: At $69.22, the stock is 19.4% below its 52-week high of $85.84, and it experienced a -38.6% max drawdown over the past year. This volatility suggests investor uncertainty about the AI strategy and execution risks.
RDNT Technical Analysis
RadNet's stock is in a strong uptrend over the past year, with a 1-year price change of +24.1%, significantly outperforming the S&P 500's +22.2% gain. The current price of $69.22 sits at 61.4% of its 52-week range (between $50.76 low and $85.84 high), indicating the stock has recovered from its lows but remains well below its peak. This positioning suggests a recovery phase, with the stock having rebounded from a -38.6% maximum drawdown, yet still facing overhead resistance near the highs.
Beta
1.38
1.38x market volatility
Max Drawdown
-38.6%
Largest decline past year
52-Week Range
$51-$86
Price range past year
Annual Return
+44.8%
Cumulative gain past year
| Period | RDNT Return | S&P 500 |
|---|---|---|
| 1m | +17.8% | +2.4% |
| 3m | +38.0% | +4.7% |
| 6m | +11.2% | +11.7% |
| 1y | +44.8% | +21.3% |
| ytd | +8.9% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RDNT Fundamental Analysis
RadNet's revenue trajectory is robust, with estimated revenue for the current year at $3.05 billion, reflecting strong demand for diagnostic imaging services. The company's gross margin is a thin 4.45%, which is typical for imaging center operators due to high fixed costs and reimbursement pressures, but the operating margin of 4.45% indicates stable cost management. Net income is slightly negative, with an EPS of -$0.0035, but the company is nearly breakeven, and analysts expect EPS to turn positive to $1.22 next year, signaling a potential inflection point. The balance sheet shows a debt-to-equity ratio of 1.71, which is elevated but manageable given the company's cash flow generation, and a current ratio of 1.76 indicates adequate liquidity. Free cash flow is not explicitly provided, but the price-to-cash-flow ratio of 17.95 suggests the company is generating positive cash flow, which supports its ability to fund growth initiatives like the Gleamer acquisition.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RDNT Overvalued?
Given the negative trailing EPS, the price-to-sales (PS) ratio is the primary valuation metric, currently at 2.63x, which is reasonable for a healthcare services company with growth potential. The forward PE of 73.4x is high, but this reflects the market's expectation of a significant earnings recovery, as analysts project EPS of $1.22 next year. The PEG ratio of 0.38 suggests that the stock is undervalued relative to its expected growth, indicating that the market may be pricing in a strong earnings rebound. Compared to the industry average PS ratio of 2.5x (based on available data), RadNet trades at a slight premium of 5%, which is justified by its AI-driven growth strategy and market leadership. Historically, the stock's valuation has been volatile, but the current PS ratio is near the lower end of its historical range, suggesting that the stock is not overvalued relative to its own past, and the market may be cautious about the near-term earnings drag from the Gleamer acquisition.
PE
-285.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable for RadNet. The company carries a debt-to-equity ratio of 1.71, indicating a leveraged balance sheet that could strain cash flows if interest rates rise or earnings underperform. Its gross margin is razor-thin at 4.45%, leaving little buffer against reimbursement cuts or cost inflation, and the current net margin is negative at -0.91%, reflecting ongoing losses. The reliance on continued revenue growth to justify the high forward PE of 73.4x means any deceleration could trigger a significant de-rating. Additionally, the $270 million Gleamer acquisition adds integration risk and may pressure near-term profitability, as evidenced by the negative EPS of -$0.0035.